Ebos GroupASX:EBO -1.21%81 ROC (Joel Greenblatt) % is 30.96% as of Dec. 2025, which is 36% below its 10-year median of 48.46. GuruFocus rates ASX:EBO with a GF Score™ of 81/100 and a GF Value™ of A$31.54 (Significantly Undervalued). The stock has 4 warning signs investors should review. Among 118 Medical Distribution companies, Ebos Group ranks better than 73.73% on this metric.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Ebos Group's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was 30.96%.
The historical rank and industry rank for Ebos Group's ROC (Joel Greenblatt) % or its related term are showing as below:
ASX:EBO'
s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 30 Med: 48.46 Max: 59.67
Current: 30
During the past 13 years, Ebos Group's highest ROC (Joel Greenblatt) % was 59.67%. The lowest was 30.00%. And the median was 48.46%.
ASX:EBO's ROC (Joel Greenblatt) % is ranked better than 73.73% of 118
companies
in the Medical Distribution industry
Industry Median: 15.345
vs ASX:EBO: 30.00
Ebos Group's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was -4.00% per year.
Ebos Group (ASX:EBO) ROC (Joel Greenblatt) % Explanation
The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.
Ebos Group ROC (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for Ebos Group's ROC (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:EBO vs MCK, CAH, COR: ROC (Joel Greenblatt) % Comparison
For the Medical Distribution subindustry, Ebos Group's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ebos Group ROC (Joel Greenblatt) % vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Ebos Group's ROC (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Ebos Group's ROC (Joel Greenblatt) % falls into.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:
EBIT stands for Earnings Before Interest and Taxes.
Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.
GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.
Note:
The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROC (Joel Greenblatt) % of 30.96% mean?
Ebos Group (ASX:EBO) has a ROC (Joel Greenblatt) % of 30.96% as of Dec. 2025. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Ebos Group and its competitors. This is 36% below median its historical median of 48.46. Over the past decade, Ebos Group's ROC (Joel Greenblatt) % has ranged from 30.00 to 59.67. According to the industry distribution chart, Ebos Group ranks #31 out of 118 companies in the Medical Distribution industry, placing it in the top 26.3%.
Is Ebos Group's ROC (Joel Greenblatt) % too high?
Ebos Group's current ROC (Joel Greenblatt) % of 30.96% is 36% below median its 10-year median of 48.46. Over the past 10 years, this metric has ranged from a low of 30.00 to a high of 59.67. The Medical Distribution industry median ROC (Joel Greenblatt) % is 15.35. Ebos Group's value of 30.96% is 101.8% above this industry median. Based on the distribution chart, Ebos Group ranks #31 out of 118 companies in the Medical Distribution industry, which is above the industry midpoint. Overall, Ebos Group has a GF Score™ of 81/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Ebos Group's ROC (Joel Greenblatt) % compare to MCK and CAH?
According to the Medical Distribution industry distribution chart, Ebos Group ranks #31 out of 118 companies for ROC (Joel Greenblatt) %. This puts Ebos Group in the upper half of its industry. The industry median ROC (Joel Greenblatt) % is 15.35. Ebos Group's value of 30.96% is 101.8% above this benchmark. Historically, Ebos Group's own ROC (Joel Greenblatt) % has ranged from 30.00 to 59.67 over the past decade. While the company's 10-year median is 48.46 vs. the industry median of 15.35, Ebos Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Medical Distribution company?
The median ROC (Joel Greenblatt) % among Medical Distribution companies is 15.35, based on 118 companies in the industry. Companies in the top quartile (top 25%) have a ROC (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ebos Group's current ROC (Joel Greenblatt) % of 30.96% is 101.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Ebos Group and its competitors. For the Medical Distribution industry, the median ROC (Joel Greenblatt) % is 15.35 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ebos Group's current ROC (Joel Greenblatt) % is 30.96%, which is 36% below median its own 10-year median of 48.46. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ebos Group stock overvalued right now?
Based on GuruFocus' analysis, Ebos Group (ASX:EBO) is currently considered Significantly Undervalued. The stock's GF Value™ is A$31.54, compared to a current price of A$17.98 — trading 43% below its estimated fair value. The current ROC (Joel Greenblatt) % is 30.96%, which is 36% below median its 10-year median of 48.46 and 101.8% above the Medical Distribution industry median of 15.35. Ebos Group's overall GF Score™ is 81/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For Ebos Group (ASX:EBO), the current ROC (Joel Greenblatt) % is 30.96% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ebos Group (ASX:EBO) Overvalued in 2026?
Based on GuruFocus' analysis, Ebos Group stock appears to be undervalued.
The current stock price of A$17.98 is trading 43% below its estimated GF Value™ of A$31.54.
GuruFocus considers Ebos Group to be Significantly Undervalued.
Key valuation signals for ASX:EBO:
ROC (Joel Greenblatt) %: 30.96% (36% below median its 10-year median of 48.46)
GF Value™: A$31.54 vs. price of A$17.98 (43% below fair value)
Industry Position: 101.8% above the Medical Distribution median (#31 of 118)
No single metric tells the full story. See the ASX:EBO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ebos is the largest pharmaceutical wholesaler across Australia and New Zealand. It services community pharmacies and hospitals, which contribute around 50% and 30% of revenue, respectively. Drug pricing and wholesale margins for PBS medicine are governed by the Australian government's Pharmaceutical Benefits Scheme, or PBS. Wholesale gross margins are capped at 7% for community pharmacy and 10% for hospitals, and ongoing price reform typically results in low-single-digit revenue growth. Aside from pharma distribution, Ebos operates an animal health product wholesale, manufacturing and retail business, as well as undertaking third party logistics services. These segments are smaller contributors to group revenue but due to the unregulated nature are higher-margin operations.
81GF Score
Get the complete analysis for ASX:EBO
ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:EBO has been successfully added to your 
